EVO Earnings Date: Nov 5, 2026 — Evotec SE
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is EVO's next earnings date?
Evotec SE (EVO) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026 at 1:00 AM ET (before market open). The consensus estimate is EPS of -$0.20 on revenue of $154.9M.
How did EVO do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Evotec SE posted EPS of -$0.15 versus the -$0.05 estimate, a miss of 150.0%. Revenue was $166.8M against a $174.6M estimate. The stock's 1-day post-earnings move was -7.8%.
How much does EVO stock move after earnings?
EVO beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.2% (up or down) in the day after earnings.
About Evotec SE
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.05 | -0.15 | -150.00% | $166.8M | ❌ Miss | -7.76% | -9.59% | -21.00% |
| 2026-05-06 | Q1 2026 | 0.08 | -0.40 | -603.75% | $183.4M | ❌ Miss | +1.25% | -6.25% | -7.19% |
| 2026-04-08 | Q4 2025 | 0.02 | 0.05 | +160.00% | $294.9M | ✅ Beat | +4.26% | +20.93% | +25.58% |
| 2025-11-05 | Q3 2025 | -0.14 | -0.14 | +0.00% | $191.6M | ➖ Inline | -15.74% | -25.19% | -18.64% |
| 2025-08-13 | Q2 2025 | -0.12 | -0.14 | -12.50% | $194.1M | ❌ Miss | +0.00% | -5.25% | -8.66% |
| 2025-05-06 | Q1 2025 | -0.24 | -0.10 | +60.42% | $210.3M | ✅ Beat | -2.88% | +0.00% | -1.68% |
| 2025-04-17 | Q4 2024 | -0.01 | -0.12 | -1100.00% | $236.1M | ❌ Miss | +10.09% | +28.75% | +24.16% |
| 2024-11-06 | Q3 2024 | -0.08 | -0.12 | -50.00% | $203.2M | ❌ Miss | -15.61% | -3.06% | +2.84% |
Showing last 8 quarters.